StreetInsider.com News Articles

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Tue, 25 Aug 2026 11:07:00 -0400

si-local-file:///var/storage/secattach/20260825/26972824.html

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Tue, 25 Aug 2026 11:07:00 -0400

si-local-file:///var/storage/secattach/20260825/26972824.html

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Mon, 24 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26969082.html

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Mon, 24 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26969082.html

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Fri, 21 Aug 2026 15:24:00 -0400

si-local-file:///var/storage/secattach/20260821/26961051.html

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Fri, 21 Aug 2026 15:24:00 -0400

si-local-file:///var/storage/secattach/20260821/26961051.html

Form 4 Vir Biotechnology, Inc. For: Aug 11 Filed by: MORE ROBERT J

Wed, 12 Aug 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26912015.html

Form 4 Vir Biotechnology, Inc. For: Aug 11 Filed by: MORE ROBERT J

Wed, 12 Aug 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26912015.html

H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR)

Mon, 10 Aug 2026 06:44:36 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $20.00 price target on Vir Biotechnology (NASDAQ: VIR).

The analyst commented: "With Phase 3 programs ECLIPSE 1, 2 and 3 all fully enrolled, topline data are expected from ECLIPSE 1 in 4Q26 and from ECLIPSE 2 and ECLIPSE 3 in 1Q27. At the European Association for the Study of the Liver (EASL) Congress in May, the complete Week 96 intent-to-treat analysis showed 88% (28/32) of patients on elebsiran (small interfering RNA, siRNA) plus tobevibart (monoclonal antibody, mAb) achieved undetectable HDV RNA versus 53% (17/32) on tobevibart monotherapy, and of 97% (31/32)

Form SCHEDULE 13G Vir Biotechnology, Inc. Filed by: STATE STREET CORP

Fri, 07 Aug 2026 11:11:00 -0400

si-local-file:///var/storage/secattach/20260807/26889326.html

Form SCHEDULE 13G Vir Biotechnology, Inc. Filed by: STATE STREET CORP

Fri, 07 Aug 2026 11:11:00 -0400

si-local-file:///var/storage/secattach/20260807/26889326.html

Vir Biotechnology (VIR) PT Lowered to $25 at Morgan Stanley

Thu, 06 Aug 2026 08:53:25 -0400

Morgan Stanley analyst Michael Ulz lowered the price target on Vir Biotechnology (NASDAQ: VIR) to $25.00 (from $27.00) while maintaining a Overweight rating.

Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c

Wed, 05 Aug 2026 17:38:59 -0400

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of $0.47, $0.14 better than the analyst estimate of $0.33. Revenue for the quarter came in at $238.94 million versus the consensus estimate of $135.88 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

Form 10-Q Vir Biotechnology, Inc. For: Jun 30

Wed, 05 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260805/26876012.html

Form 10-Q Vir Biotechnology, Inc. For: Jun 30

Wed, 05 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260805/26876012.html

Form 8-K Vir Biotechnology, Inc. For: Aug 05

Wed, 05 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26874253.html

Form 8-K Vir Biotechnology, Inc. For: Aug 05

Wed, 05 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26874253.html

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

- Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of treatment

- Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026

- Closed global strategic collaboration with Astellas and initiated additional VIR-5500 Phase 1 monotherapy and combination therapy dose-expansion cohorts in patients with metastatic prostate cancer

- Ended quarter with over $1.0 billion in cash, cash equivalents and investments

- Conference call scheduled for August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

- Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026

- Ended quarter with over $1.0 billion in cash, cash equivalents and investments

- Conference call scheduled for August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

- Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026

- Ended quarter with over $1.0 billion in cash, cash equivalents and investments

- Conference call scheduled for August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

- Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026

- Ended quarter with over $1.0 billion in cash, cash equivalents and investments

- Conference call scheduled for August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

Form SCHEDULE 13G/A Vir Biotechnology, Inc. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260731/26848909.html

Form SCHEDULE 13G/A Vir Biotechnology, Inc. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260731/26848909.html

Form 8-K Vir Biotechnology, Inc. For: Jul 20

Fri, 24 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260724/26811101.html

Form 8-K Vir Biotechnology, Inc. For: Jul 20

Fri, 24 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260724/26811101.html